Pharmaceuticals, Biotechnology and Life Sciences
86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients…
– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated – – One deep (71% tumor…
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering…
Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT…
SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel…
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that…
PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B IMC-I109V studied for the…
MENLO PARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) — Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing…
MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…
SANTA MONICA, Calif., May 18, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines…